SOLVO Biotechnology Recieves ISO 9001:2000 Quality Management System Certification
News Aug 21, 2007
SOLVO Biotechnology has announced that the company has received the UKAS accredited ISO 9001:2000 quality management system certification for the development and production of methods and reagents, contract research services.
As the leader in the development of membrane transporter assay systems SOLVO provides a wide array of in vitro ABC efflux, uptake transporter and monolayer assays as products and/or contract research services for industrial and academic organizations worldwide.
SOLVO’s solution packages answer important questions related to membrane transporters. Depending on the state of drug development pipeline SOLVO provides the adequate tool to answer transporter related concerns. High throughput membrane and cellular assays allow for inexpensive screening of large number of compounds during lead selection and optimization.
Lower throughput in vitro and in vivo assays can be used in preclinical candidate selection. Based on the Biopharmaceutical Drug Disposition Classification System SOLVO’s other assay selection scheme focuses on physicochemical properties of the compound, such as permeability and solubility.
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.